A novel transcriptional complex on the VE-cadherin promoter regulated the downregulation of VE-cadherin in the Down Syndrome Candidate Region 1 isoform 1L-mediated angiogenesis

Shiqiang Hou,Gengming Niu,Xin Liu,Pierre M Bourbon,Dongmei Zhang,Pengfei Cui,Kevin Zhao,Dezheng Zhao,Huiyan Zeng,Pierre M. Bourbon
DOI: https://doi.org/10.1016/j.mvr.2021.104209
IF: 3.75
2021-11-01
Microvascular Research
Abstract:<p>Angiogenesis is critical for many diseases. Previously, we reported that Down Syndrome Candidate Region 1 isoform 1 L (DSCR1–1 L) was one of the most up-regulated genes in <strong>endothelial cells</strong> induced by VEGF and histamine, and regulated endothelial cell proliferation and Matrigel angiogenesis in mice. However, it was not known whether DSCR1–1 L regulated angiogenesis in vivo and what was the molecular mechanism underlying it. In this study, gene knockdown and overexpression models were established to study the role of DSCR1–1 L in angiogenesis in vivo. Further, the downstream regulatory target of DSCR1–1 L was explored with molecular biological methods in vascular endothelial cells. We found that DSCR1–1 L shRNAs significantly inhibited angiogenesis induced by VEGF in mice (<em>p</em> &lt; 0.0001). In the gain-of-function assay, overexpression of DSCR1–1 L cDNA in mouse endothelium of EC-FH-DSCR1–1 L transgenic mice was sufficient to induce angiogenesis significantly (<em>p</em> &lt; 0.01). DSCR1–1 L regulated angiogenesis in the early stage by down-regulation of the VE-cadherin expression through targeting its transcription, but not mRNA stability. Three DSCR1–1 L-targeted DNA elements in the VE-cadherin promoter were identified by promoter reporter assays, among which, a novel specific transcriptional complex was found. The DNA sequence (CTTCTG) in the VE-cadherin promoter was identified to directly interact with proteins by Electrophoresis Mobility Shift Assays and DNase I footprint assay. Hence, DSCR1–1 L is an excellent therapeutic target for angiogenic diseases through down-regulating the formation of a novel transcriptional complex on the VE-cadherin promoter. DSCR1–1 L shRNAs and cDNA have the potential to be developed for clinical application. Our results also contribute significantly to the field of mechanistic studies.</p>
peripheral vascular disease
What problem does this paper attempt to address?